-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2024-06-26
TWST:NSD- (USD)
COMMON STOCK | Diagnostics & Research |
Last Closing
USD 46.47Change
-1.36 (-2.84)%Market Cap
USD 2.94BVolume
0.91MVerdict
Verdict
Values as of: 2024-06-26
COMMON STOCK | Diagnostics & Research |
Last Closing
USD 46.47Change
-1.36 (-2.84)%Market Cap
USD 2.94BVolume
0.91MVerdict
Verdict
Currency: USD
Country : USA
Symbol | Name | Price(Change) | Market Cap |
---|---|---|---|
IDXX | IDEXX Laboratories Inc |
N/A |
USD 41.65B |
ICLR | ICON PLC |
N/A |
USD 26.38B |
ILMN | Illumina Inc |
N/A |
USD 17.24B |
NTRA | Natera Inc |
N/A |
USD 13.49B |
MEDP | Medpace Holdings Inc |
N/A |
USD 12.38B |
EXAS | EXACT Sciences Corporation |
N/A |
USD 7.74B |
RDNT | RadNet Inc |
N/A |
USD 4.31B |
GH | Guardant Health Inc |
N/A |
USD 3.66B |
NEOG | Neogen Corporation |
N/A |
USD 3.63B |
SHC | Sotera Health Co |
N/A |
USD 3.21B |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|---|---|---|---|---|
ARCG:LSE | ARK Genomic Revolution UC.. | 9.48 % | 0.00 % |
N/A |
USD 2.30M |
EDOC:LSE | Global X Telemedicine & D.. | 4.07 % | 0.00 % |
N/A |
USD 4.59M |
EDOG:LSE | Global X Telemedicine & D.. | 4.07 % | 0.00 % |
N/A |
USD 0.14M |
WBIO:LSE | WisdomTree BioRevolution .. | 4.05 % | 0.00 % |
N/A |
USD 2.97M |
WDNA | 3.93 % | 0.00 % |
N/A |
N/A | |
WDNA:LSE | WisdomTree BioRevolution .. | 3.79 % | 0.00 % |
N/A |
USD 2.97M |
WRNA:XETRA | WisdomTree BioRevolution .. | 3.33 % | 0.00 % |
N/A |
USD 2.77M |
CDNA:CA | CI Bio-Revolution ETF | 3.06 % | 0.00 % |
N/A |
CAD 5.70M |
XBI | SPDR® S&P Biotech ETF | 1.49 % | 0.35 % |
N/A |
USD 6.65B |
ARKG | 0.00 % | 0.75 % |
N/A |
N/A | |
FYC | First Trust Small Cap Gro.. | 0.00 % | 0.70 % |
N/A |
USD 0.27B |
LABU | Direxion Daily S&P Biotec.. | 0.00 % | 1.14 % |
N/A |
USD 1.01B |
FYX:LSE | 0.00 % | 0.00 % |
N/A |
N/A | |
WELL:LSE | Hanetf Icav - Han-Gins He.. | 0.00 % | 0.00 % |
N/A |
USD 0.02B |
EDOC | Global X Telemedicine & D.. | 0.00 % | 0.00 % |
N/A |
USD 0.05B |
IBBJ | 0.00 % | 0.00 % |
N/A |
N/A |
Market Performance vs. Industry/Classification (Diagnostics & Research) | Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | 26.07% | 85% | B | 86% | B+ | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 26.07% | 85% | B | 86% | B+ | ||
Trailing 12 Months | |||||||
Capital Gain | 141.15% | 100% | F | 97% | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 141.15% | 100% | F | 97% | N/A | ||
Trailing 5 Years | |||||||
Capital Gain | 60.19% | 72% | C | 78% | C+ | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 60.19% | 72% | C | 76% | C+ | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | 68.05% | 89% | A- | 93% | A | ||
Dividend Return | 68.05% | 89% | A- | 93% | A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 175.22% | 15% | F | 8% | B- | ||
Risk Adjusted Return | 38.84% | 81% | B- | 71% | C- | ||
Market Capitalization | 2.94B | 78% | C+ | 84% | B |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
The stock is trading high compared to its peers median on a price to book value basis.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
The company had negative total cash flow in the most recent four quarters.
The company had negative total free cash flow in the most recent four quarters.
This stock has shown below median earnings growth in the previous 5 years compared to its sector